Related Experiment Video
Updated: May 14, 2026

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells
Published on: February 15, 2019
Trends of laboratory nonhuman primate licensing in China between 2020 and 2024: A national database analysis
Baoxu Ma1, Manying Yuan1,2, Wenxian Xiao1
1National Resource Center for Non-Human Primates, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China.
Abstract:
Nonhuman primates are critical translational models in biomedical research due to their genetic, anatomical, and physiological similarities to humans. China, once a dominant global supplier of captive-bred laboratory primates, has long maintained a national licensure system to govern their production and use. Despite this, the overall scope, spatial distribution, and institutional landscape of licensing activities for laboratory primates in China remain insufficiently characterized, limiting data-driven governance and resource planning. This study conducted a comprehensive retrospective analysis of all laboratory primate licenses issued in China between 2020 and 2024, based on data retrieved from the China Laboratory Animal Licensing Management System (LALMS). In total, 430 licenses were analyzed across production and utilization categories, temporal dynamics, geographical distribution, and institutional ownership. Utilization licenses constituted 85% of the total, while production licenses accounted for 15%. Licensing activity expanded progressively until 2023 before declining sharply in 2024. Among 31 provincial-level administrative divisions in mainland China, 28 were authorized to produce or utilize laboratory primates. Beijing and Jiangsu emerged as primary centers of licensing activity, particularly for utilization. In contrast, production licenses were predominantly concentrated in Guangxi and Yunnan. Utilization licenses exhibited broader geographic distribution than production licenses, although licensing activity was heavily concentrated in East China (31%), North China (22%), and South China (19%). The majority of licenses were held by commercial enterprises (60%), followed by universities (22%) and research institutes (18%). These findings define the temporal and spatial landscape of laboratory primate licensing in China and generate critical data to inform resource allocation, improve regulatory transparency, and promote the responsible and sustainable integration of primate models into biomedical research.
More Related Videos
10:23Absolute Quantification of Plasma MicroRNA Levels in Cynomolgus Monkeys, Using Quantitative Real-time Reverse Transcription PCR
Published on: February 12, 2018
07:43A Validatable Droplet Digital Polymerase Chain Reaction Assay for the Detection of Adeno-Associated Viral Vectors in Bioshedding Studies of Tears
Published on: July 14, 2023